|
I spent time with Bristol-Myers Squibb and Immunex/Amgen. I bailed on the research gig after many reorgs/shuffling within BMS. Left when they transferred the entire Seattle group to Lawrenceville. Did not go for that one.
With Immunex/Amgen was working as a graphic designer. Immunex was great: Amgen was not so. Could see writing on the wall that there was no future for me with the bean counters there.
I have friends in most of the biotechs/big pharma's and NO ONE feels safe. Buying and selling companies is going to be the way from here on out. This goes for small biotech and big pharma as well. The small ones will only exist if they have rock solid IP or something very promising late in development. Big ones will only make it if they keep pipelines full of "blockbusters". Either one of those scenarios are fraught with big risk and speculation.
__________________
gary
|